Mark Eisner - 04 Apr 2023 Form 4 Insider Report for FIBROGEN INC (FGEN)

Reporting relationship: Chief Medical Officer
Issuer ticker: FGEN
Reported as of: 04 Apr 2023
Net transaction value: -$172,473
SEC form: 4
Accepted by SEC: 06 Apr 2023, 16:32:26 UTC
Prior SEC filing: 10 Mar 2023
Next SEC filing: 05 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Cecelia Monoarfa-Taime, Attorney-in-fact

Key filing fact

Mark Eisner filed Form 4 for FIBROGEN INC (FGEN) on 06 Apr 2023.

Key facts

This page summarizes Mark Eisner's Form 4 filing for FIBROGEN INC (FGEN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 06 Apr 2023, 16:32.

Change

Previous filing in this sequence was filed on 10 Mar 2023.
Current net transaction value: -$172,473.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FGEN transaction

Common Stock

Sale

Transaction value: $172,473
Shares: -9,182
Change %: -5.2%
Price: $18.78^*
Shares after: 165,994
Date: 04 Apr 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.